US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actuate Therapeutics Inc

9.04

+0.04000.44%

Pre-market: 8.52-0.5200-5.75%04:15 EDT

Volume:48.03K

Turnover:431.40K

Market Cap:176.57M

PE:-2.77

High:9.12

Open:8.82

Low:8.68

Close:9.00

Loading ...

Overview Company News Filings

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission

Sydney Morning Herald

BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc

BRIEF-Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC

Actuate Therapeutics Files Prospectus to Offer, Sale of up to 3.9 Mln Shares by B. Riley Principal Capital Ii, Llc -SEC Filing

THOMSON REUTERS

Actuate Therapeutics Inc - Have the Right to Sell up to $50 Million Newly Issued Shares - SEC Filing

THOMSON REUTERS

Actuate Therapeutics Inc - Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - SEC Filing

THOMSON REUTERS

‘Completely unrealistic’: Four-day Aussie work week seemingly a long way off

Sydney Morning Herald

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, Incyte

BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating

Actuate Therapeutics Initiated at Buy by HC Wainwright & Co.

Actuate Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $20

THOMSON REUTERS

ACTU targets blue-collar seats to protect Labor, defend IR gains

The Australian Financial Review

Actuate Therapeutics completes enrollment in Phase 2 trial of elraglusib

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With Folfirinox and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer

THOMSON REUTERS

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

Assault on retail penalty rates may spread to other jobs: ACTU

The Australian Financial Review

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":9.04,"timestamp":1745524800000,"preClose":9,"halted":0,"volume":48030,"hourTrading":{"tag":"盘前","latestPrice":8.52,"preClose":9.04,"latestTime":"04:15 EDT","volume":101,"amount":860.4000120000001,"timestamp":1745568917760},"delay":0,"floatShares":5961432,"shares":19531636,"eps":-3.258828,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"04-25 05:05:52 EDT","open":8.82,"high":9.12,"low":8.68,"amount":431398.8987,"amplitude":0.048889,"askPrice":14.37,"askSize":100,"bidPrice":3.64,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.258828,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":9.04,"preHourTrading":{"tag":"盘前","latestPrice":8.52,"preClose":9.04,"latestTime":"04:15 EDT","volume":101,"amount":860.4000120000001,"timestamp":1745568917760},"postHourTrading":{"tag":"盘后","latestPrice":9.04,"preClose":9.04,"latestTime":"16:00 EDT","volume":48,"amount":433.91999999999996,"timestamp":1745524801479},"volumeRatio":0.40926822492699816},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":5961432,"roa":"-255.41%","roe":"--","lyrEps":-3.258828,"volumeRatio":0.40926822492699816,"shares":19531636,"dividePrice":0,"high":9.12,"amplitude":0.048889,"preClose":9,"low":8.68,"week52Low":5.51,"pbRate":"1694.72","week52High":11.73,"institutionHeld":0,"latestPrice":9.04,"eps":-3.258828,"divideRate":0,"volume":48030,"delay":0,"ttmEps":-3.258828,"open":8.82,"prevYearClose":7.96,"prevWeekClose":8,"prevMonthClose":6.77,"prevQuarterClose":6.77,"fiveDayClose":8.23,"twentyDayClose":8,"sixtyDayClose":9.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529363399","title":"Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529363399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529363399?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:24","pubTimestamp":1745418240,"startTime":"0","endTime":"0","summary":"- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel  in first-line treatment of metastatic pancreatic ductal adenocarcinoma . CHICAGO and FORT WORTH, Texas, April 23, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that topline clinical data from the randomized Phase 2 study  evaluating elraglusib have been selected for oral presentation at the 2025 American Society of Clinical Oncology  Annual Meeting, to take place May 30- June 3, in Chicago, Illinois.Abstract Title: Preliminary results from the randomized phase 2 study  of elraglusib in combination with gemcitabine/nab-paclitaxel  versus GnP alone in patients  with previously untreated metastatic pancreatic ductal adenocarcinoma .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-present-elraglusib-phase-2-142400619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AFG","ACTU","BK4117","BK4107"],"gpt_icon":0},{"id":"2528190277","title":"Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528190277","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528190277?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891200,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, April 17, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research  Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR.Poster presentation details:Title: Elraglusib, a glycogen synthase kinase 3 beta  inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancerSession Title: Phase II Clinical Trials 2Session Date and Time: April 29, 2025, 2:00 PM - 5:00 PMLocation: Poster Section 50Abstract Presentation Number: CT212","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-present-promising-data-elraglusib-120000563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","ACTU","BK4139","IE00B19Z4B17.USD","IE0031619046.USD","IE00B66KJ199.SGD","BK4157","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2524421463","title":"ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=2524421463","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524421463?lang=en_us&edition=fundamental","pubTime":"2025-04-03 08:38","pubTimestamp":1743640723,"startTime":"0","endTime":"0","summary":"Union leader Sally McManus has fronted the Fair Work Commission to push for a big minimum wage increase for workers.","market":"nz","thumbnail":"https://images.perthnow.com.au/publication/C-18250086/007f86a8bae46d76ad8291e42c44f792cef6d921-16x9-x0y192w2048h1152.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-18250086/007f86a8bae46d76ad8291e42c44f792cef6d921-16x9-x0y192w2048h1152.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/business/actu-pushes-for-45-per-cent-lift-in-minimum-wage-at-fair-work-commission-c-18250086","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/business/actu-pushes-for-45-per-cent-lift-in-minimum-wage-at-fair-work-commission-c-18250086","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["XAO.AU","ACTU","BK4139","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2522057953","title":"BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2522057953","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522057953?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165619,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc March 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC - ENTERS STOCK PURCHASE AGREEMENT WITH B. RILEY PRINCIPAL CAPITAL II, LLC - SEC FILINGACTUATE THERAPEUTICS INC - HAVE THE RIGHT TO SELL UP TO $50 MILLION  NEWLY ISSUED SHARES  - SEC FILINGFurther company coverage: ACTU.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2522578074","title":"BRIEF-Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578074","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578074?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:56","pubTimestamp":1743162988,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLCMarch 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS FILES PROSPECTUS TO OFFER, SALE OF UP TO 3.9 MILLION SHARES BY B. RILEY PRINCIPAL CAPITAL II, LLC -SEC FILINGFurther company coverage: ACTU.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2522036526","title":"Actuate Therapeutics Files Prospectus to Offer, Sale of up to 3.9 Mln Shares by B. Riley Principal Capital Ii, Llc -SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522036526","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522036526?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:25","pubTimestamp":1743157554,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2522525508","title":"Actuate Therapeutics Inc - Have the Right to Sell up to $50 Million  Newly Issued Shares  - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522525508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522525508?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:06","pubTimestamp":1743156379,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2522052559","title":"Actuate Therapeutics Inc - Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522052559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522052559?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:06","pubTimestamp":1743156379,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB02A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2520911669","title":"‘Completely unrealistic’: Four-day Aussie work week seemingly a long way off","url":"https://stock-news.laohu8.com/highlight/detail?id=2520911669","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520911669?lang=en_us&edition=fundamental","pubTime":"2025-03-19 12:44","pubTimestamp":1742359498,"startTime":"0","endTime":"0","summary":"Corporations are getting good results with four-day work weeks, but the prospect of such a change Australia-wide seems unlikely.","market":"us","thumbnail":"https://images.perthnow.com.au/publication/C-18091434/958011663f3871cb4bd7efba7ec745b45fcfe0f2-16x9-x0y192w2048h1152.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-18091434/958011663f3871cb4bd7efba7ec745b45fcfe0f2-16x9-x0y192w2048h1152.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/business/completely-unrealistic-four-day-aussie-work-week-seemingly-a-long-way-off-c-18091434","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/business/completely-unrealistic-four-day-aussie-work-week-seemingly-a-long-way-off-c-18091434","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["XJO.AU","XKO.AU","ACTU","XAO.AU","BK4139"],"gpt_icon":0},{"id":"2520339505","title":"BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2520339505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520339505?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:41","pubTimestamp":1742233265,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL4N3Q00YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","VTVT","SAIC","NCLH","PEP","JOBY","AMT","BX","CTRA","CCI","FDS","LIVN","INCY","ANET","METC","OBDC","ASLE","XOM","TRGP","CVX","SFM","STNG","BANC","NEM","AEO","ACTU","RIVN"],"gpt_icon":1},{"id":"2520352912","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, Incyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2520352912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520352912?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:08","pubTimestamp":1742216915,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, IncyteEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL6N3Q00BJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["METC","NVDD","INCY","LU2265009873.SGD","NVDS.UK","ACTU","IE00BLSP4452.SGD","LU0211328371.USD","LU0708995401.HKD","LU2168564065.EUR","IE000M9KFDE8.USD","BK4517","NVDY","LU0096362180.USD","NCLH","RIVN","ASLE","INTC","LU2237957902.USD","SNVD.UK","LU0345770308.USD","LU0187121727.USD","LU2458330243.SGD","STNG","LU0109391861.USD","TSYW.SI","LU2430703251.USD","LU0868494617.USD","3NVD.UK","LU1066051225.USD","LU2168564495.EUR","NVDU","2NVD.UK","ZIM","NVD3.UK","LU0225283273.USD","LU1923622291.USD","NVIW.SI","NVDS","NVD2.UK","LU0057025933.USD","LU0985320562.USD","LU1815333072.USD"],"gpt_icon":1},{"id":"2520615542","title":"BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2520615542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520615542?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:43","pubTimestamp":1742211831,"startTime":"0","endTime":"0","summary":"BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with \"buy\" rating ** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close** In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death ** Brokerage says the trial data for the therapy, elraglusib, \"positions it as a frontrunner among competition\" for pancreatic cancer treatments ** Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need ** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033** ACTU has fallen 8.9% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL4N3Q00SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","ACTU"],"gpt_icon":0},{"id":"2520549585","title":"Actuate Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520549585","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520549585?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:03","pubTimestamp":1742209380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 07:03 ET (11:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACTU","BK4139"],"gpt_icon":0},{"id":"2520517448","title":"Actuate Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2520517448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520517448?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:05","pubTimestamp":1742205918,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nAZN3KCXVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2516549532","title":"ACTU targets blue-collar seats to protect Labor, defend IR gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2516549532","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516549532?lang=en_us&edition=fundamental","pubTime":"2025-03-03 02:00","pubTimestamp":1740938400,"startTime":"0","endTime":"0","summary":"Unions will marshal thousands of activists to shore up the blue-collar vote in dozens of at-risk regional and outer-suburban seats to keep Labor in government and defend industrial relations changes t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/work-and-careers/workplace/actu-targets-blue-collar-seats-to-protect-labor-defend-ir-gains-20250218-p5lcyn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["BK4161","BK4588","LU0256863811.USD","IR","LU0256863902.USD","LU0124384867.USD","LU0417517546.SGD","LU1978683503.SGD","ACTU","BK4139","BK4585","SG9999001440.SGD"],"gpt_icon":0},{"id":"2514091666","title":"Actuate Therapeutics completes enrollment in Phase 2 trial of elraglusib","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091666","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091666?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:25","pubTimestamp":1740489944,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced the completion of patient enrollment in the ongoing Phase 2 trial of FOLFIRINOX in combination with elraglusi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-completes-enrollment-in-phase-2-trial-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-completes-enrollment-in-phase-2-trial-of-elraglusib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ACTU","BK4139"],"gpt_icon":0},{"id":"2514096218","title":"Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With Folfirinox and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096218?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA2PHXYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2514670099","title":"Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Ade","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031941/0/en/Actuate-Announces-Completion-of-Enrollment-in-a-Phase-2-Trial-of-Elraglusib-in-Combination-with-FOLFIRINOX-and-Losartan-in-Patients-with-Previously-Untreated-Metastatic-Pancreatic-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2510327329","title":"Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510327329","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510327329?lang=en_us&edition=fundamental","pubTime":"2025-02-12 18:55","pubTimestamp":1739357746,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?Given this risk, we thought we'd take a look at whether Actuate Therapeutics  shareholders should be worried about its cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-therapeutics-nasdaq-actu-good-105546392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","IE00BGHQF748.EUR","IE00B64PRP62.GBP","QLD","NQmain","SQQQ","MNQmain","PSQ","BK4585",".IXIC","BK4139","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","TQQQ","BK4112","USAW.SI","USJW.SI","IE00B3QW5Z07.USD","LU2095319765.USD","ACTU","LU2210149790.SGD","NVIW.SI","TSYW.SI","NDAQ"],"gpt_icon":1},{"id":"2506626875","title":"Assault on retail penalty rates may spread to other jobs: ACTU","url":"https://stock-news.laohu8.com/highlight/detail?id=2506626875","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506626875?lang=en_us&edition=fundamental","pubTime":"2025-01-28 14:52","pubTimestamp":1738047120,"startTime":"0","endTime":"0","summary":"The Australian Council of Trade Unions fears a push by major retailers to exempt senior staff from weekend rates and overtime could form a precedent for other industries, and has called for political parties to commit to protecting penalty rates.Coles, Woolworths, Kmart and Costco have united with other retail chains like 7-Eleven, T2 and Mecca to back an Australian Retailers Association application to the Fair Work Commission to relax rules on rostering, breaks and other minimum conditions in the retail industry award.Loading...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/work-and-careers/workplace/assault-on-retail-penalty-rates-may-spread-to-other-jobs-actu-20250128-p5l7mz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["LU0820561818.USD","LU1066051498.USD","LU2095319765.USD","LU1551013425.SGD","LU0079474960.USD","LU2125154778.USD","LU0471298694.HKD","LU0820561909.HKD","LU1035775433.USD","BK4550","LU1116320901.HKD","IE00B5TLWC47.USD","XKO.AU","LU2237438978.USD","LU2360106947.USD","BK4581","LU0689472784.USD","LU1496350171.SGD","LU2360032135.SGD","BK4533","IE00BKVL7J92.USD","LU1551013342.USD","XJO.AU","LU0385154629.USD","IE0008368304.USD","LU2210149790.SGD","BK4504","LU1496350502.SGD","LU1116320737.USD","COST","LU0265550359.USD","LU0265550946.USD","LU0471298777.SGD","BK4588","XAO.AU","LU1069344957.HKD","LU2125154935.USD","LU1066053197.SGD","BK4596","LU0417517546.SGD","BK4155","LU0943347566.SGD","BK4585","LU1323610961.USD","BK4139","IE00BZ1G4Q59.USD","LU0234572021.USD","ACTU","LU0234570918.USD","LU0256863811.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1745380800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2025-04-23","current":-6.098865,"percent":0.127907,"low":-7.551405,"twenty":-5.989834,"median":-5.540019,"eighty":-4.992661,"high":-3.846419,"avg":-5.520705,"sd":0.562591,"marketCap":166409538},"quantilePoints":[{"date":"2024-08-16","current":-6.123063,"twenty":-6.192654,"median":-6.024237,"eighty":-5.763747,"marketCap":170040047},{"date":"2024-08-23","current":-5.540019,"twenty":-6.078798,"median":-5.925411,"eighty":-5.709316,"marketCap":153848669},{"date":"2024-08-30","current":-5.595075,"twenty":-6.012125,"median":-5.708628,"eighty":-5.532512,"marketCap":155377600},{"date":"2024-09-06","current":-5.608839,"twenty":-5.962574,"median":-5.601957,"eighty":-5.528759,"marketCap":155759833},{"date":"2024-09-13","current":-5.471267,"twenty":-5.922658,"median":-5.608839,"eighty":-5.528759,"marketCap":151939417},{"date":"2024-09-20","current":-5.636367,"twenty":-5.87999,"median":-5.601957,"eighty":-5.515244,"marketCap":156524298},{"date":"2024-09-27","current":-4.113941,"twenty":-5.797406,"median":-5.560665,"eighty":-5.483587,"marketCap":118557030},{"date":"2024-10-04","current":-4.749671,"twenty":-5.732715,"median":-5.540019,"eighty":-4.899514,"marketCap":136877705},{"date":"2024-10-11","current":-4.852689,"twenty":-5.672153,"median":-5.519373,"eighty":-4.774612,"marketCap":139846513},{"date":"2024-10-18","current":-5.042459,"twenty":-5.644693,"median":-5.512491,"eighty":-4.820157,"marketCap":145315371},{"date":"2024-10-25","current":-5.754096,"twenty":-5.644693,"median":-5.505609,"eighty":-4.820157,"marketCap":165823589},{"date":"2024-10-31","current":-5.801538,"twenty":-5.759014,"median":-5.512491,"eighty":-4.836423,"marketCap":167190804},{"date":"2024-11-08","current":-5.930311,"twenty":-5.818052,"median":-5.520312,"eighty":-4.866244,"marketCap":170901815},{"date":"2024-11-15","current":-5.869501,"twenty":-5.914108,"median":-5.540019,"eighty":-4.932663,"marketCap":166995487},{"date":"2024-11-22","current":-6.178422,"twenty":-5.935733,"median":-5.560665,"eighty":-4.991319,"marketCap":175784724},{"date":"2024-11-29","current":-5.581175,"twenty":-5.958745,"median":-5.588125,"eighty":-5.03075,"marketCap":158792200},{"date":"2024-12-06","current":-6.013664,"twenty":-5.987349,"median":-5.608839,"eighty":-5.042459,"marketCap":171097131},{"date":"2024-12-13","current":-5.691014,"twenty":-5.987349,"median":-5.622603,"eighty":-5.049236,"marketCap":161917262},{"date":"2024-12-20","current":-4.839764,"twenty":-5.96561,"median":-5.608839,"eighty":-5.042459,"marketCap":137698033},{"date":"2024-12-27","current":-5.766528,"twenty":-5.96448,"median":-5.608839,"eighty":-5.040117,"marketCap":164065742},{"date":"2025-01-03","current":-5.464471,"twenty":-5.964763,"median":-5.595075,"eighty":-5.046525,"marketCap":155471822},{"date":"2025-01-10","current":-5.491931,"twenty":-5.962017,"median":-5.595075,"eighty":-5.051947,"marketCap":156253088},{"date":"2025-01-17","current":-5.869501,"twenty":-5.952793,"median":-5.601957,"eighty":-5.10132,"marketCap":166995487},{"date":"2025-01-24","current":-7.551405,"twenty":-5.965328,"median":-5.622603,"eighty":-5.16928,"marketCap":214847996},{"date":"2025-01-31","current":-6.061719,"twenty":-6.031513,"median":-5.643249,"eighty":-5.172381,"marketCap":172464345},{"date":"2025-02-07","current":-6.05554,"twenty":-6.061192,"median":-5.677284,"eighty":-5.192919,"marketCap":172288561},{"date":"2025-02-14","current":-5.306578,"twenty":-6.058374,"median":-5.670419,"eighty":-5.230693,"marketCap":150979546},{"date":"2025-02-21","current":-5.375227,"twenty":-6.05554,"median":-5.643249,"eighty":-5.225451,"marketCap":152932709},{"date":"2025-02-28","current":-4.757385,"twenty":-6.049288,"median":-5.622603,"eighty":-5.16928,"marketCap":135354237},{"date":"2025-03-07","current":-4.76425,"twenty":-6.047989,"median":-5.595075,"eighty":-5.042459,"marketCap":135549553},{"date":"2025-03-14","current":-5.114361,"twenty":-6.034259,"median":-5.57431,"eighty":-5.03075,"marketCap":145510688},{"date":"2025-03-21","current":-5.003646,"twenty":-6.020529,"median":-5.560665,"eighty":-5.03075,"marketCap":136526135},{"date":"2025-03-28","current":-5.425986,"twenty":-6.013664,"median":-5.543435,"eighty":-5.03075,"marketCap":148049800},{"date":"2025-04-04","current":-5.168287,"twenty":-6.0068,"median":-5.540019,"eighty":-4.997657,"marketCap":141018411},{"date":"2025-04-11","current":-5.089546,"twenty":-5.987349,"median":-5.520321,"eighty":-4.981461,"marketCap":138869931},{"date":"2025-04-17","current":-5.891275,"twenty":-5.969958,"median":-5.530635,"eighty":-4.987756,"marketCap":160745364},{"date":"2025-04-23","current":-6.098865,"twenty":-5.989834,"median":-5.540019,"eighty":-4.992661,"marketCap":166409538}],"updateTime":1745542649428}}}